In October 2013, Jürgen Dinger, Sabine Möhner, and Klaas Heinemann published the article “Cardiovascular Risk Associated With the Use of an Etonogestrel-Containing Vaginal Ring,” hereafter “Cardiovascular Risk,” in the journal Obstetrics and Gynecology. The authors enrolled patients in the study who were new users of either a vaginal contraceptive ring known as NuvaRing or a combined oral contraceptive pill. A combined oral contraceptive pill contains a formulation of the hormones progesterone and estrogen. They followed up with the patients for two to four years after they had started either hormonal contraceptive treatment to record the incidence of specific cardiovascular events. The authors found that the risks of cardiovascular events when starting use of either NuvaRing or a combined hormonal contraceptive pill were similar to each other in the patients they studied. The results of “Cardiovascular Risk” affirmed the results of similar studies and stated that the risk of cardiovascular events was similar in NuvaRing users to other contraceptive users.
Details
- “Cardiovascular Risk Associated With the Use of an Etonogestrel-Containing Vaginal Ring” (2013), by Jürgen Dinger, Sabine Möhner, and Klaas Heinemann
- Jacobson, Molly (Author)
- Nichols, Cole (Editor)
- Arizona State University. School of Life Sciences. Center for Biology and Society. Embryo Project Encyclopedia. (Publisher)
- Arizona Board of Regents (Publisher)
- Technology
- Contraceptives, Vaginal
- Oral contraceptives
- Oral contraceptives--Side effects
- Thrombosis
- Thromboembolism
- Blood Coagulation
- Contraceptives, Oral, Combined
- Contraceptive Devices, Female
- Vaginal Rings
- Cardiovascular Risk Factors
- Cardiovascular Risk
- Venous Thromboembolism
- Embolism and Thrombosis
- Reproduction
- NuvaRing
- etonogestrel
- Technologies
- Hormonal contraceptive side effects
- Prospective observational study
- Arterial blood clots
- Venous blood clots